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Introduction
Cell locomotion is critical for normal embryonic development, 
cell-mediated immunity, and wound healing, as well as for 
pathological conditions such as infl  ammation and tumor metas-
tasis. The process of cell motility depends on the ability of a cell 
to extend a leading edge in a polarized fashion and to adhere to 
an underlying substratum. Integrin receptors for extracellular 
matrix are concentrated at sites of substratum attachment, pro-
viding the structural support necessary for lamellar protrusion. 
Recent work has revealed that substratum adhesion sites display 
functional heterogeneity, with the small adhesions near the 
leading edge of a cell representing the sites of greatest mechani-
cal force transmission to the substratum (Beningo et al., 2001). 
Heterogeneity in the molecular composition of adhesion sites 
is likely to account for their functional diversity (Zamir et al., 
1999; Katz et al., 2000).
In mammalian cells, one component of substratum adhe-
sions that is associated with mature focal adhesions, but not 
with Rac-induced nascent adhesions that are concentrated at the 
leading edge, is zyxin (Zaidel-Bar et al., 2003). Zyxin is a LIM 
domain protein that has been implicated in the regulation of 
  actin assembly, cell division control, and nuclear–cytoplasmic 
communication (Nix and Beckerle, 1997; Beckerle, 1998; 
  Hirota et al., 2000). A role for zyxin in actin assembly was pro-
posed when it was recognized that a series of proline-rich 
repeats in the ActA protein of the intracellular pathogen Listeria 
monocytogenes are also present in zyxin (Golsteyn et al., 1997; 
Niebuhr et al., 1997). The FPPPP sequences present in L. mono-
cytogenes ActA stimulate actin assembly on the pathogen’s sur-
face and promote bacterial motility within the cytoplasm of a 
eukaryotic host. A common mechanism by which zyxin and 
ActA are thought to promote actin polymerization involves re-
cruitment of Ena/VASP proteins, which are proposed to act by 
recruiting profi  lin-actin and by controlling the access of cap-
ping protein to the barbed ends of actin fi  laments (Fradelizi 
et al., 2001; Bear et al., 2002).
Imaging of zyxin in living cells has revealed that zyxin 
accumulation at adhesion sites is highly dynamic. Zyxin levels 
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F
ocal adhesions are specialized regions of the cell 
surface where integrin receptors and associated 
proteins link the extracellular matrix to the actin 
cytoskeleton. To deﬁ  ne the cellular role of the focal ad-
hesion protein zyxin, we characterized the phenotype 
of ﬁ   broblasts in which the zyxin gene was deleted by 
homologous recombination. Zyxin-null ﬁ  broblasts display 
enhanced integrin-dependent adhesion and are more 
migratory than wild-type ﬁ  broblasts, displaying reduced 
dependence on extracellular matrix cues. We identiﬁ  ed 
differences in the proﬁ   les of 75- and 80-kD tyrosine-
  phosphorylated proteins in the zyxin-null cells. Tandem 
array mass spectrometry identiﬁ   ed both modiﬁ  ed  pro-
teins as isoforms of the actomyosin regulator caldesmon, 
a protein known to inﬂ  uence contractility, stress ﬁ  ber forma-
tion, and motility. Zyxin-null ﬁ  broblasts also show deﬁ  cits 
in actin stress ﬁ  ber remodeling and exhibit changes in the 
molecular composition of focal adhesions, most notably 
by severely reduced accumulation of Ena/VASP proteins. 
We postulate that zyxin cooperates with Ena/VASP pro-
teins and caldesmon to inﬂ  uence integrin-dependent cell 
motility and actin stress ﬁ  ber remodeling.
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are low near the leading edge of a migrating cell, where high 
tension and propulsive forces are generated (Beningo et al., 
2001). Moreover, the accumulation of zyxin at substratum ad-
hesion sites is correlated with cessation of membrane protrusion 
(Zaidel-Bar et al., 2003) and with a dramatic reduction in trac-
tion forces (Beningo et al., 2001). Because of these intriguing 
observations that suggest a link between the presence of zyxin 
and the properties of substratum adhesion sites, we sought to 
assess the consequences of eliminating zyxin function for cell 
adhesion, motility, and actin organization.
Results
Isolation and characterization 
of zyxin-null ﬁ  broblasts
Murine zyxin is a 564-aa LIM protein (Fig. 1 A) whose bind-
ing partner repertoire had suggested a role in actin assembly, 
cell cycle control, cell motility, and cell signaling. To directly 
assess the contributions of zyxin to cell function, we have 
isolated fi  broblasts from mice in which the zyxin gene is dis-
rupted by homologous recombination (Hoffman et al., 2003). 
Neither full-length nor truncated zyxin protein is present in 
the zyxin−/− cells (Fig. 1 B). Loss of gene function can lead 
to compensatory up-regulation of other family members. Two 
proteins that are closely related to zyxin, the lipoma preferred 
partner (LPP; Petit et al., 2000) and thyroid receptor-interacting 
protein 6 (TRIP6; Yi and Beckerle, 1998), are also expressed 
in fi  broblasts. We detected no alteration in the level of expres-
sion of either LPP or TRIP6 in the zyxin−/− cells (Fig. 1 C), 
which is consistent with the view that cells do not compensate 
for the elimination of zyxin by modulating the expression of 
these highly related proteins.
Some focal adhesion constituents depend on the presence 
of their binding partners for their stability (Fukuda et al., 2003). 
Therefore, we examined whether the levels of zyxin-binding 
partners were compromised when zyxin was absent and de-
tected no differences in the levels of several zyxin-binding part-
ners (Fig. 1 D). Likewise, other focal adhesion proteins including 
vinculin, talin, integrin-linked kinase (ILK), FAK, paxillin, and 
src were detected at similar levels in wild-type and zyxin−/− 
cells (Fig. 1 E).
Elimination of zyxin does not alter 
mitotic progression
Zyxin displays mitosis-dependent phosphorylation and has 
been shown to interact directly with the h-warts/LATS1 tumor 
suppressor, a serine/threonine kinase implicated in cell cycle 
control (Hirota et al., 2000). Disturbance of the LATS1–zyxin 
interaction by use of a dominant-interfering LATS1 truncation 
product (LATS1 aa 136–700) was shown to interfere with zyxin 
localization during mitosis and delay mitotic progression, 
leading to the suggestion that LATS1-dependent recruitment of 
zyxin to the mitotic apparatus is required for regulated exit from 
mitosis (Hirota et al., 2000).
With the availability of zyxin−/− cells, we were able to 
test directly whether zyxin is essential for normal mitotic pro-
gression. We detected no change in LATS1 protein levels in the 
zyxin−/− cells (Fig. 1 C); therefore, zyxin is not essential for 
LATS1 stability. To look for specifi  c changes in the cell cycle 
caused by loss of zyxin, fl  ow cytometric analysis of cell cycle 
Figure 1.  Immunoblot analysis of zyxin-null ﬁ  bro-
blasts. (A) Domains of zyxin include the α-actinin bind-
ing site, four ActA Ena/VASP binding repeats, two 
nuclear export signals (NES), and three LIM domains. 
Sites of epitopes for zyxin-speciﬁ  c  antibodies  1D1 
(zyxin aa 29–47) and B71 (zyxin aa 336–355) are 
identiﬁ  ed by an asterisk. (B) Cell lysates of wild-type 
(+/+) and zyxin-null (−/−) ﬁ  broblasts were electro-
phoresed (10% SDS-PAGE) and either stained to con-
ﬁ   rm equal protein loading (Coomassie blue) or 
transferred to nitrocellulose for immunoblot analysis 
with anti-zyxin aa 29–47 (1D1) and anti-zyxin aa 
336–355 (B71). (C–E) Immunoblot analysis of wild-
type and zyxin−/− cells for expression of zyxin fam-
ily members (C), zyxin-binding partners (D), and other 
focal adhesion proteins (E).
Figure 2.  The cell cycle is not altered in zyxin-null cells. 
(A) Flow cytometry proﬁ  les of the propidium-iodide DNA 
content per cell (2 and 4 n) for wild-type (+/+) and zyxin-
null (−/−) ﬁ  broblasts. (B) Graph of cell cycle distribution 
of wild-type and zyxin−/− ﬁ broblasts modeled as diploid 
populations. Data represent the mean ± SEM. n = 4.ZYXIN-NULL FIBROBLASTS • HOFFMAN ET AL. 773
progression in exponentially growing wild-type and zyxin−/− 
cells was used (Fig. 2 A). No statistically signifi  cant differences 
in cell cycle progression (Fig. 2 B) or the percentage of binucle-
ate cells (not depicted) were observed. These results illustrate 
that, at least in fi  broblasts, mitotic progression and cytokinesis 
can proceed normally in the absence of zyxin.
Zyxin-null cells display enhanced migration
Many of zyxin’s binding partners and biochemical activities 
suggest that it may play a role in integrin- and actin-linked pro-
cesses. Therefore, we focused the balance of our analysis on the 
possible role of zyxin in motility, adhesion, and cytoarchitec-
ture. To determine if loss of zyxin altered cell motility, the 
 behavior  of  zyxin−/− cells was evaluated using a monolayer 
wound assay. In blind studies, zyxin−/− fi  broblasts were con-
sistently observed to reach the midline of the wound sooner 
than the wild-type cells (Fig. 3 A). Quantitative analysis re-
vealed that the zyxin−/− cells displayed a mean migration ve-
locity of 32 μm/h compared with the wild-type migration rate 
of 18 μm/h (Fig. 3 B). The enhanced migration of zyxin−/− 
fi  broblasts suggests that zyxin acts as a negative regulator of 
cell motility.
Zyxin-null cells appear primed for migration, 
independent of matrix cues
Integrin-dependent adhesion is essential for communicating 
intracellular contractility to the underlying extracellular matrix 
and is necessary to drive motility. To explore the contribution of 
zyxin to cell motility in greater detail, we examined the hapto-
tactic migration of wild-type and zyxin−/− cells toward a vari-
ety of integrin ligands using a Boyden chamber transwell 
migration assay (Fig. 4 A). We observed a striking difference in 
Figure 3.  Monolayer wound assays demonstrate enhanced migration of ﬁ  broblasts lacking zyxin. A wound was scraped across monolayer wild-type and 
zyxin-null ﬁ  broblasts, and migration was monitored by time-lapse microscopy. (A) Time points (0, 4, 8, and 12 h) of wild-type ﬁ  broblasts (top) and 
zyxin−/− ﬁ  broblasts (bottom). (B) The results were examined in a blind fashion and converted into rate measurements (the distance to the midline of the 
wound over the time it took for cells to reach the midline; mean ± SEM; n = 4). Primary MEFs were used for wound assays. **, P < 0.005.
Figure 4.  Boyden chamber transwell assays demon-
strate enhanced migration of zyxin-null ﬁ  broblasts. 
(A) Transwell migration (6 h) toward culture medium 
with 10% FBS on BSA or 20 μg/ml of collagen type I 
(Col I), collagen type IV (Col IV), ﬁ  bronectin (Fib), lam-
inin (Lam), superﬁ  bronectin (Sﬁ  b), or vitronectin (Vit). 
Data represent the mean ± SEM. n = 4. (B) Wild-type 
and zyxin-null cell migration with increasing ﬁ  bronec-
tin concentration (n = 4). (C) Transwell Matrigel in-
vasion assays (24 h) of wild-type and zyxin-null 
ﬁ  broblasts, and zyxin-null cells expressing a GFP-zyxin 
transgene. (D) GFP-zyxin expressed in zyxin−/− 
  ﬁ   broblasts localized properly to focal adhesions. 
(E) Immunoblot analysis of zyxin and GFP-zyxin. 
  Immortalized cell lines were used for transwell 
  migration   assays. *, P < 0.05; **, P < 0.005.JCB • VOLUME 172 • NUMBER 5 • 2006  774
haptotactic motility when comparing wild-type and zyxin−/− 
cells. Except in the cases of 20 μg/ml fi  bronectin or vitronectin, 
the zyxin-null cells displayed statistically signifi  cant enhance-
ment of migration, relative to wild-type cells.
Matrix proteins have differential, concentration- dependent 
capacities to stimulate cell migration. As can be seen in Fig. 4 B, 
migration of wild-type fi  broblasts exhibited sensitivity to fi  bro-
nectin concentration, whereas zyxin-null fi  broblasts   migrated 
effi  ciently independent of fi  bronectin concentration. The migra-
tion of the zyxin-null cells in the absence of matrix cues was 
statistically indistinguishable from the maximal migration of 
wild-type cells toward fi  bronectin. Zyxin-null cells also dis-
played enhanced migratory potential relative to their wild-type 
counterparts in a Matrigel invasion assay (Fig. 4 C). Introduc-
tion of a GFP-tagged version of zyxin into the null cells resulted 
in suppression of cell migration (Fig. 4 C). GFP-zyxin localized 
Figure 5.  Adhesion to ECM proteins is enhanced in zyxin-
null ﬁ   broblasts, but integrin expression is unchanged. 
(A) Wild-type and zyxin-null ﬁ   broblasts were evaluated for 
adhesion to vitronectin, laminin, collagen IV, and ﬁ  bronectin 
(5  μg/ml; 25  min). After removal of unattached cells, the 
adherent cells were ﬁ   xed, stained with toluidine blue, and 
quantitated by absorbance at 620 nm. Data represent the 
mean  ± SEM. n  = 4. (B) GFP-zyxin reintroduced into 
zyxin−/− cells   decreased the adhesion to laminin, relative 
to zyxin−/− cells. (C) Immunoblot analysis of wild-type and 
zyxin−/−   ﬁ  broblasts for integrins α3, α5, αV, β1 and β3. 
Immortalized cell lines were used for adhesion assays. 
*, P < 0.05; **, P < 0.005.
Figure 6.  An altered tyrosine-phosphorylated protein in zyxin-null cells is identiﬁ  ed as the actomyosin regulator caldesmon. Indirect immunoﬂ  uorescence 
of pY-containing proteins in wild-type (A) and zyxin-null (B) ﬁ  broblasts. (C) Immunoblot analysis of equivalent amounts of protein from wild-type and 
zyxin−/− cells using pY-speciﬁ  c antibody 4G10 detected a 75-kD signal (arrowheads) in wild-type cells, and an 80-kD signal (arrowhead) in zyxin−/− 
cells. (D) 2D gel electrophoresis and anti-pY immunoblot analysis identiﬁ  ed a slower mobility series of pY spots from zyxin-null ﬁ  broblasts compared with 
wild-type ﬁ  broblasts. (E) Wild-type and zyxin-null pY-positive spots of interest were excised from 2D gels, partially digested with trypsin, and then subjected 
to LC-MS/MS for protein sequence analysis. Both sets of spots contained multiple peptide sequences for the actomyosin regulator caldesmon, which are 
shown aligned with l-caldesmon coding exons1′–13. Exons 3b and 4, which would be found in h-caldesmon, are shown above the l-caldesmon structure. 
(F) Immunoblot for caldesmon in wild-type and zyxin−/− cell lysates separated by 10% SDS-PAGE. Short exposure (left) showed nonmuscle caldesmon 
(l-caldesmon) migrating between 75–80 kD and longer exposure (right) identiﬁ  ed the 140-kD smooth-muscle caldesmon (h-caldesmon). (G) Tissue extracts 
(lung, bladder, and spleen) from wild-type (+/+), zyxin-heterozygous (+/−), and zyxin-null (−/−) mice were electrophoresed, transferred to nitrocellu-
lose, and probed for zyxin (B71 rabbit anti-serum; top) and caldesmon (bottom).ZYXIN-NULL FIBROBLASTS • HOFFMAN ET AL. 775
as expected at focal adhesions in the zyxin−/− cells (Fig. 4 D) 
and was expressed at levels approximating that of zyxin in wild-
type cells (Fig. 4 E). GFP, which did not affect motility, dis-
played diffuse cellular localization (not depicted). The successful 
rescue of the null cells by reintroduction of a zyxin transgene 
  illustrates that the migration phenotype observed for the 
zyxin−/− cells is directly attributable to loss of zyxin.
Zyxin-null cells display enhanced adhesion 
without any increase in integrin expression
We next tested whether altered cell–substratum adhesion might 
account for the enhanced motility of the zyxin−/− cells. 
Zyxin-null fi  broblasts were more adherent than wild-type fi  bro-
blasts when plated on a variety of extracellular matrix proteins 
(Fig. 5 A), and reexpression of GFP-zyxin in null cells re-
sulted in reduced adhesion (Fig. 5 B). One possible explanation 
for the enhanced cell adhesion observed in the zyxin−/− cells 
could be elevated integrin expression. However, immunoblot 
analysis revealed no difference in integrin levels or subunit 
  expression (Fig. 5 C).
Distinct proﬁ  le of tyrosine-phosphorylated 
proteins in zyxin-null ﬁ  broblasts
The behavior of zyxin-null fi  broblasts on integrin ligands sug-
gested that cells lacking zyxin might somehow be primed for 
integrin-dependent adhesion and migration. One molecular 
hallmark of the integrin activation state is enhanced tyrosine 
phosphorylation of proteins such as FAK, which is a tyrosine 
kinase that colocalizes with zyxin at focal adhesions. Therefore, 
we compared the subcellular distributions and molecular mass 
profi  les of tyrosine-phosphorylated proteins in wild-type and 
zyxin-null cells. Both wild-type and zyxin-null cells displayed 
phosphotyrosine (pY) associated with focal adhesions (Fig. 6, 
A and B), and Western immunoblot analysis of pY-containing 
proteins revealed no apparent difference in the region where 
FAK migrates (Fig. 6 C). However, the wild-type cells displayed 
a 75-kD tyrosine-phosphorylated protein (pY75) that showed 
reduced abundance in zyxin-null cells. In contrast, we observed 
an 80-kD tyrosine-phosphorylated protein (pY80) in the zyxin-
null cells that was not evident in the wild-type cells. Using 
two-dimensional (2D) gel electrophoresis of wild-type and 
zyxin-null cell lysates, followed by Western immunoblot with 
antiphosphotyrosine antibody, both pY75 and pY80 were 
  resolved as a cluster of isoelectric point variants ranging from 
 6.5 to 8.0 (Fig. 6 D).
The actomyosin regulator caldesmon 
is altered in zyxin-null cells
Mass spectrometric (LC-MS/MS) sequence analysis of the pro-
tein found four pY75 2D gel spots derived from wild-type cells 
and four pY80 2D gel spots derived from zyxin-null cells, such as 
those in Fig. 6 D, and identifi  ed all eight tyrosine-phosphorylated
spots as caldesmon (Fig. 6 E). Caldesmon is an actomyosin 
  regulator that infl  uences stress fi  ber formation, cell contractility, 
and cell motility (Wang, 2001). There are two major isoforms of 
caldesmon derived by alternative splicing (Fig. 6 E): nonmuscle 
or low molecular weight caldesmon (l-caldesmon) and smooth 
muscle or high molecular weight caldesmon (h-caldesmon; 
Wang, 2001). Our sequence results are consistent with recovery 
of l-caldesmon. With the exception of sequence encoded by 
exon 1′, which was only obtained for pY75 isolated from wild-
type cells, sequence from all other classical l-caldesmon exons 
(Hayashi et al., 1992; Guo and Wang, 2005) were represented 
and were nearly identical for pY75 and pY80 (Fig. 6 E).
In wild-type mouse fi  broblasts, a caldesmon-specifi  c anti-
body detected a prominent 75-kD immunoreactive band, as well 
as a minor 80-kD immunoreactive band, which is consistent 
with l-caldesmon, whereas zyxin-null fi  broblasts displayed only 
the slower migrating 80-kD species (Fig. 6 F). A similar quanti-
tative shift to a slower mobility species occurred for the 140-kD 
h-caldesmon in the zyxin-null fi  broblasts, as seen in a longer 
exposure (Fig. 6 F, right). This shift in caldesmon mobility was 
Figure 7.  Caldesmon protein in wild-type and zyxin-null ﬁ  broblasts. 
  Fibroblasts were grown for 24 h in high (10% FBS) and low (0.5% FBS)  serum, 
and then collected for immunoblot analysis. (A) Phospho-ser527/789-
speciﬁ  c antibody detected caldesmon from both wild-type and zyxin-null 
cells, with a greater signal in high serum conditions (as expected for the 
phosphorylation-speciﬁ  c antibody). The caldesmon-speciﬁ  c immunoblot 
conﬁ  rmed approximately equivalent levels of caldesmon in the lysates. 
(B) Incubation of ﬁ  broblast lysates with lambda-phosphatase followed by 
immunoblot analysis for caldesmon and paxillin. (C) His-tagged mouse 
l-caldesmon was expressed in wild-type and zyxin-null   ﬁ  broblasts, and 
then evaluated by immunoblot analysis using his-speciﬁ  c and caldesmon-
  speciﬁ  c antibodies. (D) Immunoblot analysis of wild-type, zyxin-null, and 
zyxin-null cells expressing GFP-zyxin, with caldesmon- and zyxin-speciﬁ  c 
antibodies.JCB • VOLUME 172 • NUMBER 5 • 2006  776
detected in multiple zyxin-null primary fi  broblast isolates, as 
well as in immortalized zyxin-null fi  broblast lines (unpublished 
data). Moreover, the caldesmon mobility shift was observed in 
cells derived from zyxin knock-out mice generated from two 
independently targeted embryonic stem cell lines (not depicted) 
and in a variety of tissues, including lung, bladder, and spleen, 
which were isolated directly from the zyxin-null mice (Fig. 6 G). 
The slower migrating caldesmon isoform is evident only in 
tissues derived from homozygous mutant animals, suggesting 
that complete loss of zyxin is required to promote the change 
in caldesmon.
Posttranslational modiﬁ  cation does 
not account for the caldesmon isoform 
variation observed in the zyxin-null cells
Phosphorylation can affect a protein’s electrophoretic mobility 
and, in the case of caldesmon, is known to regulate its ability to 
control contractility and integrin-dependent motility (Wang, 
2001). We tested directly whether l-caldesmon from wild-type 
and zyxin-null cells was differentially phosphorylated on 
Ser497 and Ser527, two ERK-dependent phosphorylation sites 
implicated in regulation of caldesmon function (D’Angelo 
et al., 1999). Both the 75- and 80-kD caldesmon species were 
  recognized with the phosphospecifi  c antibody (Fig. 7 A). For a 
more global assessment of whether differential phosphorylation 
might be responsible for the caldesmon mobility difference we 
have observed, we treated cell lysates from wild-type and zyxin-
null cells with phosphatase and assayed caldesmon and control 
paxillin protein mobility by SDS-PAGE (Fig. 7 B). Although 
the phosphatase treatment resulted in the collapse of paxillin 
bands indicative of dephosphorylation, no impact on caldesmon 
mobility was observed, suggesting that phosphorylation is un-
likely to account for the altered caldesmon mobility seen in the 
zyxin-null cells. To directly test whether caldesmon is subject 
to differential posttranslational modifi   cation that affects its 
mobility, we transfected wild-type and zyxin-null cells with a his-
caldesmon cDNA expression construct and monitored mobility 
of the expressed protein with Western immunoblot. The mobil-
ity of the his-tagged caldesmon was indistinguishable in wild-
type and zyxin-null cells, whereas the endogenous caldesmon 
exhibited the mobility shift (Fig. 7 C). Collectively, our results 
suggest that differential posttranslational modifi  cation of calde-
smon is not likely to be responsible for the altered caldesmon 
mobility we observe in the zyxin-null cells. Re-expression of 
zyxin does not restore caldesmon to its wild-type mobility 
(Fig. 7 D), which illustrates that the phenotypes observed in the 
Figure 8.  Localization of proteins in wild-type and 
zyxin-null ﬁ   broblasts demonstrate the importance 
of zyxin for proper localization of Mena and VASP. 
  Protein localization in wild-type (+/+) and zyxin-null 
(−/−) cells was evaluated by indirect immunoﬂ  uores-
cence microscopy using antibodies speciﬁ  c for zyxin 
(A and B; rabbit polyclonal antiserum B71), vinculin 
(C and D), Mena (E and F), and VASP (G and H). 
Wild-type cells display colocalized Mena (I) and vin-
culin (J) at focal adhesions. Mena failed to localize 
normally to zyxin-null focal adhesions (K) although 
vinculin persisted (L). Expression of GFP-zyxin in 
zyxin−/− cells restored the localization of Mena to 
focal adhesions (M), colocalizing with vinculin (N). 
To show the enhanced LPP focal adhesion staining 
(arrows) in ﬁ  broblasts lacking zyxin, a mixed popula-
tion of wild-type (+/+) and zyxin-null (−/−) cells was 
stained for LPP (O) and for zyxin (P; mouse mono-
clonal antibody 1D1).ZYXIN-NULL FIBROBLASTS • HOFFMAN ET AL. 777
zyxin-null cells are linked to loss of zyxin and are not attribut-
able to alteration of caldesmon.
Depletion of Mena and VASP from focal 
adhesions of zyxin-null cells
Zyxin is concentrated in the focal adhesions of wild-type fi  bro-
blasts (Fig. 8 A); no immunoreactivity is detected in zyxin-null 
cells (Fig. 8 B). Elimination of zyxin did not lead to changes in 
focal adhesion morphology or number, as assessed by qualita-
tive inspection of vinculin localization (Fig. 8, C and D). The 
distributions of several other focal adhesion markers, including 
FAK and paxillin, also appeared unperturbed in the zyxin-null 
cells (unpublished data). In contrast, we detected a dramatic 
diminution in the localization of the zyxin-binding partners, 
Mena and VASP, at focal adhesions (Fig. 8, E–H; and Fig. S1, 
available at http://www.jcb.org/cgi/content/full/jcb.200512115/
DC1) even though their cellular levels were unchanged (Fig. 1 C). 
In double-labeling experiments, it was evident that Mena colo-
calized with vinculin at focal adhesions of wild-type cells (Fig. 8, 
I and J) and was depleted from vinculin-rich focal adhesions in 
zyxin-null cells (Fig. 8, K and L). Thus, the altered Mena 
  localization was not attributable to loss of focal adhesion 
  structures. Expression of GFP-zyxin in the null cells restored 
  localization of Mena to vinculin-rich focal adhesions (Fig. 8, 
M and N). Similar results were obtained for VASP (unpublished 
data). These observations are consistent with a major role for 
zyxin in localizing Ena/VASP family members at focal adhe-
sions. Residual Mena and VASP accumulation at focal adhesions 
in the zyxin−/− cells likely refl  ects the presence of other focal 
adhesion proteins that can dock Ena/VASP family members. For 
example, both vinculin and LPP are present in focal adhesions 
and have the capacity to bind Ena/VASP proteins (Brindle et al., 
1996; Petit et al., 2000). Interestingly, LPP was detected more 
prominently at focal adhesions of zyxin-null cells, as compared 
with cocultured wild-type cells (Fig. 8, O and P).
Zyxin-null cells fail to build robust 
actin stress ﬁ  bers when stimulated 
with jasplakinolide
The mislocalization of Ena/VASP proteins and the alteration 
of caldesmon observed in the zyxin-null cells raised the pos-
sibility that actin fi  lament assembly or organization might be 
disturbed when zyxin function is compromised. Likewise, 
  previous work involving expression of a dominant-negative 
zyxin deletion fragment (Nix et al., 2001), RNA interference 
  (Harborth et al., 2001), and exposure of cells to mechanical   stimuli 
Figure 9.  Zyxin-null cells fail to augment 
  actin stress ﬁ  bers in response to jasplakinolide. 
Wild-type (A) and zyxin-null (B) ﬁ  broblasts 
were treated with vehicle or jasplakinolide 
and then ﬁ   xed and stained by phalloidin. 
Jasplakinolide induced thick actin stress ﬁ  bers 
in wild-type cells (C), but noticeably thinner 
and less robust actin in zyxin−/− cells (D). 
A method to quantitate an SFTI was developed 
using a computer algorithm based on erosion 
ﬁ   ltering (E), as described in Materials and 
methods. 20 images of phalloidin-stained cells 
were randomly recorded, and the average of 
SFTI was compared using analysis of variance 
between groups. (F) No difference between 
wild-type and zyxin−/− actin ﬁ  laments  was 
detected in untreated controls, but a statisti-
cally signiﬁ  cant difference between jasplakino-
lide-treated wild-type and zyxin−/− ﬁ broblasts 
was observed. A population of jasplakinolide-
treated zyxin-null ﬁ   broblasts, some of which 
were expressing GFP-zyxin (G), was stained 
with phalloidin (H). More robust actin stress 
ﬁ  bers were observed in the null cells that ex-
pressed GFP-zyxin. (I) SFTI analysis conﬁ  rmed 
that reintroduced zyxin enhanced the actin 
  ﬁ   laments in zyxin-null cells. Data represent 
the mean  ± SEM of 33 measurements. 
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(Yoshigi et al., 2005) suggested that zyxin might be required 
for actin cytoskeletal assembly or maintenance. To assess this 
possibility, we compared the actin cytoskeletons of wild-type 
and zyxin-null cells using phalloidin staining (Fig. 9, A and B). 
The presence of actin fi  lament arrays in the zyxin-null fi  bro-
blasts illustrated that zyxin was not absolutely essential for es-
tablishment and maintenance of actin stress fi  bers. To explore 
whether we might detect an effect of eliminating zyxin when 
cells were challenged to reorganize actin arrays, we compared 
the response of wild-type and zyxin-null fi  broblasts with the 
membrane- permeable drug jasplakinolide which stabilizes actin 
fi  laments and decreases the critical concentration of monomers 
required for polymerization (Bubb et al., 2000). Jasplakinolide-
treated wild-type fi  broblasts developed robust actin fi  lament 
arrays detected by phalloidin staining, but jasplakinolide-treated 
zyxin-null fi  broblasts did not exhibit such robust stress fi  ber ar-
rays (Fig. 9, C and D). To quantitate a stress fi  ber thickness 
index (SFTI), we used an “erosion” spatial fi  ltering approach 
to calculate decay constants of brightness curves (Fig. 9 E; see 
Materials and methods). This analysis confi  rmed that there was 
no statistically signifi  cant difference in phalloidin-stained actin 
fi  laments between untreated wild-type and zyxin-null fi  broblasts 
(Fig. 9 F). However, jasplakinolide-induced actin stress fi  bers in 
wild-type fi  broblasts were thicker than the fi  bers in zyxin-null 
fi  broblasts (Fig. 9 F). When GFP-zyxin was expressed in the 
zyxin-null cells, the ability of the cells to generate robust ac-
tin fi  lament arrays in response to jasplakinolide was restored. 
Zyxin-null cells expressing GFP-zyxin (Fig. 9 G) showed more 
robust actin stress fi  bers (Fig. 9 H) after exposure to jasplakino-
lide than adjacent cells that were not expressing the transgene. 
Rescue of the zyxin-null cells’ ability to build robust stress fi  -
bers by expression of GFP-zyxin was confi  rmed by quantitative 
SFTI analysis (Fig. 9 I).
Dynamic regulation of zyxin localization 
during stress ﬁ  ber remodeling
To begin to assess how zyxin might contribute to the cellular re-
sponse to jasplakinolide, we examined the behavior of zyxin in 
jasplakinolide-treated cells. As can be seen in Fig. 10 (A and B), 
zyxin underwent a dramatic redistribution in response to expo-
sure of cells to jasplakinolide. Zyxin was lost from focal adhe-
sions and accumulated along the actin stress fi  bers (Fig. 10, 
B and C). Under those conditions, zyxin was colocalized with 
caldesmon along actin fi  laments (Fig. 10, D–F). In untreated 
fi  broblasts, zyxin was colocalized with vinculin at focal adhe-
sions (Fig. 10, G–I). In contrast to zyxin, which left focal adhe-
sions in response to jasplakinolide, vinculin was retained 
at focal adhesions (Fig. 10, J–L), illustrating the specifi  city of 
zyxin’s redistribution and also illustrating that the focal adhe-
sions were not disassembling in response to jasplakinolide. 
In contrast with vinculin, which was retained at focal adhesions 
in cells exposed to jasplakinolide, Ena/VASP proteins redistrib-
uted from focal adhesions to actin fi  laments concomitant with 
zyxin redistribution (Fig. 10, M and N). This VASP redistribu-
tion to actin stress fi  bers depended on the presence of zyxin 
(Fig. 10 O). VASP accumulation in lamellar extensions was 
zyxin independent (Fig. 10 O).
Figure 10.  Jasplakinolide induces zyxin and VASP localization to actin 
ﬁ  laments. Wild-type ﬁ  broblasts treated with jasplakinolide (JAS) or DMSO 
(control) were evaluated by indirect immunoﬂ  uorescence  microscopy. 
Zyxin localization in control ﬁ   broblast (A) and in jasplakinolide-treated 
ﬁ  broblast (B). (C) Phalloidin staining of F-actin in jasplakinolide-treated ﬁ  bro-
blast. Jasplakinolide-treated ﬁ  broblast stained for caldesmon (D) and zyxin 
(E). (F) Caldesmon (pink) and zyxin (green) merge to white with colocaliza-
tion. (G) Vinculin at focal adhesions in control ﬁ  broblasts colocalizes with 
zyxin (H) as seen in I (merge to white with colocalization). (J) Vinculin at 
focal adhesions in jasplakinolide-treated ﬁ  broblasts and zyxin (K) along 
actin ﬁ  laments. (L) Merge (white) of vinculin (pink) and zyxin (green) signals 
shows the loss of colocalization upon jasplakinolide treatment. (M) Focal 
adhesion and rufﬂ  e localization of VASP in wild-type ﬁ  broblast. (N) VASP 
localizes along actin stress ﬁ  bers in a jasplakinolide-treated wild-type ﬁ  bro-
blast. (O) In a zyxin-null ﬁ  broblast, VASP fails to translocate to actin stress 
ﬁ  bers in response to jasplakinolide.ZYXIN-NULL FIBROBLASTS • HOFFMAN ET AL. 779
Discussion
Focal adhesions serve as sites of substratum attachment, signal 
transduction, and actin fi  lament anchorage. We have demon-
strated that elimination of the LIM protein zyxin by targeted 
gene disruption affects cell adhesion, migration, and stress fi  ber 
remodeling. Our analysis identifi  es several molecular altera-
tions in the zyxin-null cells that provide insight into the mecha-
nism by which loss of zyxin affects these processes.
Elimination of zyxin by targeted gene 
disruption enhances ﬁ  broblast adhesion 
and motility
Zyxin-null cells display enhanced adhesion to integrin ligands 
and enhanced migration in both wound healing and haptotactic 
motility assays. Of particular interest, zyxin-null cells behave as 
if they are insensitive to contextual cues provided by extracellu-
lar matrix and, instead, appear primed for adhesion. It is inter-
esting that studies in which zyxin localization and traction force 
generation in migrating cells were simultaneously analyzed 
demonstrated that zyxin accumulation at adhesion sites is in-
versely correlated with traction strength (Beningo et al., 2001). 
The high traction adhesions with relatively low zyxin accumu-
lation are concentrated near the advancing edge of a cell and 
represent key regions for driving motility. Our fi  ndings are con-
sistent with a model in which zyxin reduces the capacity for 
generating strong traction forces. In that view, when zyxin is 
absent, as in our knock-out cells, high affi  nity integrin attach-
ments that generate strong traction forces may persist, leading 
to enhanced motility. As we will discuss later in the study, the 
loss of zyxin also affects the actin cytoskeleton, in particular 
actin stress fi  bers, and the enhanced motility of the zyxin-null 
cells could also result from that change.
Our fi  nding that knockout of zyxin is associated with en-
hanced cell motility is consistent with studies in which stable 
expression of the oncoprotein associated with Ewing’s sarcoma 
was shown to result in decreased zyxin levels and a correspond-
ing increase in motility (Amsellem et al., 2005). However, the 
increased motility of the zyxin-null cells contrasts with previ-
ous fi  ndings in which zyxin function was probed using a nonge-
netic approach. In that case, microinjection of a peptide derived 
from the NH2 terminus of zyxin was used to displace zyxin 
from its normal subcellular location and decreased cell motility 
was observed (Drees et al., 1999). The peptide inhibition ap-
proach is distinct from the genetic approach in several ways. 
In the case in which the zyxin gene is disrupted or expression is 
down-regulated, cellular proteins that normally bind to zyxin 
would be free to circulate in the absence of zyxin. On the other 
hand, in the case of peptide-induced displacement of zyxin, 
many of these partners may still be bound to zyxin but not 
  present in their normal location, which may have distinct 
 functional  consequences.
The fact that zyxin-null mice are viable and fertile 
(Hoffman et al., 2003) is somewhat surprising, given the cellular 
phenotypes associated with loss of zyxin function; however, this 
is not without precedence. There are several cases in which the 
loss-of-function phenotype at the whole organism level appears 
less severe and provides less mechanistic insight compared with 
cell-level analysis. For example, MyoD knock-out mice fail to 
display muscle defects (Rudnicki and Jaenisch, 1995), whereas 
cell-based assays revealed a role for MyoD in muscle differentia-
tion. In the case of zyxin, our fi  ndings suggest that unchallenged 
organisms are relatively insensitive to a twofold increase in fi  bro-
blast motility or that the functional defi  cits observed in vitro are 
somehow masked in vivo. It will be interesting in future studies 
to challenge the zyxin-null mice to assess whether the enhanced 
cell motility observed in vitro might be evident as a hyperactive 
infl  ammatory response or enhanced tumor cell invasiveness.
Zyxin provides the primary docking site 
for Ena/VASP proteins at focal adhesions
Previous works have demonstrated that the NH2-terminal EVH1 
domain of Ena/VASP interacts with the FPPPP (ActA) motif 
and is responsible for focal adhesion targeting (Gertler et al., 
1996; Niebuhr et al., 1997; Drees et al., 2000). Several pro-
teins that display ActA repeats are present in focal adhesions 
(Renfranz and Beckerle, 2002), and the relative contribution of 
each to Ena/VASP recruitment had not been established. Our 
analysis of Ena/VASP localization in cells lacking zyxin dem-
onstrates that zyxin provides the primary focal adhesion target-
ing information for Ena/VASP. The observation that LPP levels 
appear elevated in zyxin-null focal adhesions suggests that en-
hanced localization of LPP may provide some compensation 
for the elimination of zyxin. Other focal adhesion constituents 
are unaffected by elimination of zyxin, thus, underscoring the 
specifi  city of the Ena/VASP defi  ciency and providing defi  nitive 
evidence that zyxin is not essential for the assembly or mainte-
nance of focal adhesions.
Lack of zyxin does not disturb the capacity of Ena/VASP 
to concentrate at the leading edge, suggesting that zyxin does 
not normally contribute to the recruitment of Ena/VASP to this 
region of a cell. This result is consistent with studies reporting 
that Ena/VASP proteins in cell surface projections are not exten-
sively colocalized with zyxin (Rottner et al., 2001). Moreover, 
a  recent study has identifi  ed another ActA repeat-containing 
protein, lamellipodin, as critical for targeting Ena/VASP to sites 
of lamellipodial protrusion (Krause et al., 2004). Thus, it ap-
pears that zyxin plays a key role in targeting Ena/VASP to focal 
adhesions, but not to other cell areas, where Ena/VASP accumu-
lation depends on other factors.
Cells that lack zyxin display deﬁ  cits 
in actin cytoskeletal remodeling
Zyxin promotes actin assembly when targeted to the plasma 
membrane or to mitochondria, and this effect depends on the 
ability of zyxin to bind Ena/VASP proteins (Golsteyn et al., 
1997; Fradelizi et al., 2001). Moreover, exposure of fi  broblasts 
to mechanical force induces the reinforcement of actin stress 
 fi bers by a mechanism that has been shown to require zyxin 
  (Yoshigi et al., 2005). We demonstrate that treatment of wild-
type fi  broblasts with the actin assembly-promoting drug, jas-
plakinolide, results in thickening of stress fi   bers, and this 
response is abrogated in zyxin-null cells. These fi  ndings illus-
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The importance of zyxin for the proper subcellular local-
ization of Ena/VASP proteins suggests that zyxin could contrib-
ute to enhancement of actin stress fi  ber assembly by recruitment 
of Ena/VASP proteins to the fast growing ends of actin fi  laments 
that are anchored at focal adhesions. At those sites, Ena/VASP 
proteins could enhance actin assembly by recruitment of pro-
fi  lin-actin and/or by interference with the ability of capping pro-
tein to block fi  lament barbed ends (Bear et al., 2002). In that 
regard, it is intriguing that exposure of wild-type cells to jas-
plakinolide (this study) or mechanical force (Yoshigi et al., 
2005) is accompanied by a dramatic shift in the subcellular 
  localization of both zyxin and Ena/VASP from focal adhesions 
onto actin stress fi  bers, whereas many other focal adhesion pro-
teins remain associated with the substratum attachment sites.
The mechanism by which zyxin translocates from focal 
adhesions to actin stress fi  bers in response to jasplakinolide or 
physiological effectors that induce actin fi  lament stabilization/
assembly remains to be clarifi  ed. One possibility is that zyxin 
and its partners are released from the focal adhesions into the 
cytoplasm and can then assemble along the lengths of actin 
stress fi  bers. An alternative possibility is that zyxin and its part-
ners are primarily associated with the barbed ends of actin fi  la-
ments and stimulation of actin assembly, e.g., by jasplakinolide, 
causes their centripetal movement because of the addition of 
new monomer at focal adhesions. From this perspective, the mo-
bilization of zyxin and Ena/VASP from focal adhesions to actin 
stress fi  bers could provide a marker for actin polymerization.
Modiﬁ  cation of the actomyosin regulator, 
caldesmon, in zyxin-null cells
Caldesmon negatively regulates actomyosin-dependent con-
tractility (Wang, 2001), and overexpression of caldesmon re-
sults in the diminishment of actin stress fi  bers (Helfman et al., 
1999). Our fi  ndings illustrate that zyxin has an opposite, en-
hancing impact on stress fi  bers. Given this functional relation-
ship, it is interesting that we consistently observe an altered 
mobility isoform of caldesmon in cells derived from mice in 
which the zyxin gene is ablated. A modifi  cation of caldesmon 
that abrogated its capacity to inhibit contractility could provide 
compensation for the loss of zyxin. In this view, one might ex-
pect a more severe stress fi  ber disruption if zyxin function were 
compromised in the absence of the hypothesized compensatory 
change in caldesmon. Indeed, it has been reported that instanta-
neous elimination of zyxin expression by siRNA results in loss 
of stress fi  bers (Harborth et al., 2001).
Additional work is required to elucidate the precise mech-
anism underlying the caldesmon isoform shift observed in 
zyxin-null cells; however, our results suggest that altered post-
translational modifi  cation is not responsible for the change in 
caldesmon mobility. Moreover, the fact that we observe the 
slower mobility caldesmon variant in homozygous mutant cells, 
but not in tissues derived from heterozygous mice, provides evi-
dence that the change in caldesmon is not caused by an insertional 
mutagenesis event in the caldesmon gene that constitutively 
  affects the size of the protein product. Expression of an alterna-
tively spliced form of caldesmon that is regulated at either the 
transcriptional or translational level could account for the 
  observed caldesmon mobility shift in the zyxin-null cells. 
L-caldesmon is encoded by 11 invariant exons (2, 3a, and 5–13; 
Hayashi et al., 1992; Payne et al., 1995), and we detected se-
quence encoded by each of these exons in caldesmon isolated 
from both wild-type and zyxin-null cells. Thus, variation in the 
usage of these exons is not likely to account for the mobility 
shift observed in the zyxin-null cells. Our sequence analysis 
confi  rmed the usage of exon 1′ in l-caldesmon isolated from 
wild-type cells. However, we did not detect exon 1′ encoded se-
quence in caldesmon derived from zyxin-null cells, suggesting 
that differential inclusion of the alternative exon 1 or an unchar-
acterized 5′ exon may account for the caldesmon variation ob-
served in the zyxin-null cells.
Molecular heterogeneity of caldesmon has been previ-
ously noted; however, the molecular mechanism for this iso-
form diversity has not been explained (Okamoto et al., 2000). 
Usage of exon 1 is associated with tumor neovasculature for 
glioblastomas, oligodendrogliomas, and astrocytomas (Zheng 
et al., 2004). In addition, a caldesmon mobility shift similar to 
what we describe is also observed in mice lacking calponin, an-
other regulator of actomyosin-dependent contractility (Matthew 
et al., 2000). This observation reinforces the concept that ex-
pression of alternative forms of caldesmon may provide a means 
for compensation when contractility regulation is compromised 
by mutation, and provides a link between zyxin and this func-
tion. It is interesting that reintroduction of zyxin into the null 
cells does not result in reversion of caldesmon to the species 
found in wild-type cells. We interpret this to mean that the 
change is genetically or epigenetically fi  xed in the absence of 
zyxin. Importantly, because reexpression of zyxin in the null 
cells does restore normal actin architecture, Ena/VASP localiza-
tion, and motility, these phenotypes can be directly attributed to 
perturbation of zyxin levels.
Zyxin as a modulator of actin function 
and cell motility
We have shown that cells lacking zyxin display augmented ad-
hesive properties, enhanced migration, reduced capacity to build 
robust actin stress fi  bers in response to a chemical stimulus, and 
disturbed focal adhesion accumulation of actin regulators in the 
Ena/VASP family. Reintroduction of a zyxin transgene into the 
null cells causes reversion of these phenotypes. We have also 
uncovered an unusual property of both zyxin and VASP pro-
teins, which is their specifi  c mobilization from focal adhesions 
to actin stress fi  bers in response to an agent that stimulates actin 
assembly. The critical role of zyxin in chemically triggered ac-
tin assembly is revealed by analysis of zyxin-null cells, which 
fail to respond effi  ciently to jasplakinolide. Finally, we have 
identifi  ed an unanticipated link between caldesmon and zyxin 
based on the demonstration that targeted deletion of the zyxin 
gene is consistently accompanied by an alteration in the con-
tractility modulator caldesmon. Our analysis of zyxin function, 
coupled with previous work on caldesmon, suggests that these 
two proteins are functionally linked, perhaps antagonizing each 
other to regulate actin stress fi  ber assembly.
Disturbance of cytoskeletal architecture has long been 
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cells lack robust actin stress fi  ber arrays, which are associated 
with enhanced motility. Interestingly, zyxin levels are dramati-
cally reduced in invasive bladder carcinoma (Sanchez-Carbayo 
et al., 2002) and in a Ewing’s sarcoma model system (Amsellem 
et al., 2005). Methylation-sensitive silencing of zyxin expres-
sion has also been shown to be a characteristic of several breast 
cancer cell lines (Wang et al., 2005). The results reported here 
suggest a mechanism by which reduction in zyxin expression 
could contribute to tumor progression by affecting cytoarchitec-
ture and motility.
Materials and methods
Antibodies
Commercial antibody sources included ICN Biomedicals (α-actinin), Sigma-
Aldrich (talin and vinculin), BD Biosciences (caldesmon, ILK, paxillin, and 
integrins α3, αV, β1, β3), Upstate Cell Signaling (FAK 4–47, pY-4G10, 
and src), Santa Cruz Biotechnology, Inc. (FAK C-20 and pY-20), CHEMICON 
International, Inc. (integrin α5), Cell Signaling Technology (p-Tyr-100), and 
Qbiogene (VASP). Zyxin (B71, B72, and 1D1), TRIP6 (B65; Hoffman et al., 
2003), and phospho-Ser527/789-caldesmon (D’Angelo et al., 1999) 
antibodies were previously described. Other investigators supplied anti-LPP 
MP2 (M. Petit and J.M. Van de Ven, University of Leuven, Leuven, Belgium; 
Petit et al., 2000), anti-Mena 2197 and anti-VASP 2010 (F. Gertler, 
Massachusetts Institute of Technology, Boston, MA; Bear et al., 2000), and 
anti-warts kinase/LATS C2 (T. Hirota and H. Saya, Kumamoto University, 
Hanjo, Japan; Hirota et al., 2000).
Mouse ﬁ  broblasts
Primary mouse embryonic ﬁ  broblasts (MEFs) were derived from day 14 
embryos of wild-type or zyxin-null mice (backcrossed nine generations into 
the inbred C57BL/6 line [Charles River Laboratories] to ensure genetic ho-
mogeneity, except at the zyxin locus; Hoffman et al., 2003). Primary MEFs 
were expanded and frozen as passage 2 stocks. For experiments, the cells 
were thawed and used within a week (passages 4–6) as early-passage 
MEFs. To generate immortalized cell lines, cells were cultured from tissue 
(torso) explants of newborn mice. After spontaneous immortalization 
(generally passages 8–12), viable cell lines were isolated using cloning 
cylinders, expanded, and frozen for future use. All cells were grown in high 
glucose DME supplemented with pyruvate, glutamine, penicillin/streptomycin 
(Invitrogen), 10% FBS (HyClone) at 37°C, and 5% CO2. Cells were treated 
with 100 nM of jasplakinolide or DMSO control for 2 h in DME supple-
mented with 10% FBS (Bubb et al., 2000). Unless speciﬁ  ed in the ﬁ  gure 
legend, experiments used both primary and immortalized cell lines, 
with similar results obtained for both. Immortalized cells were used for 
  rescue experiments.
An enhanced GFP-mouse zyxin DNA was inserted into the retroviral 
vector LINXv-myc (Hoshimaru et al., 1996) and Phoenix-Eco cells (American 
Type Culture Collection) were used to generate retrovirus. Zyxin-null 
  ﬁ  broblast cell lines were infected and sorted for GFP to select enhanced 
GFP-zyxin-myc–expressing cells. Caldesmon-6histidine DNA was in-
serted into pBABEpuro and transiently transfected with Lipofectamine 
2000 (Invitrogen).
Cell cycle, adhesion, and migration assays
Propidium iodide staining of DNA and ﬂ  ow cytometry followed established 
procedures (Iida et al., 2004) using a FACScan instrument and CellQuest 
software (Becton Dickinson).
Adhesion assays were performed essentially as previously described 
(Xu et al., 1998), with 10
5 cells seeded for 25 min into ECM-coated wells, 
and were performed four times with two pairs of independently derived 
wild-type and zyxin−/− cell lines.
Monolayer wound assay was performed as previously described 
(Xu et al., 1998), with conﬂ  uent MEFs in optical 35-mm plates on a 37°C 
heated stage apparatus (Bioptechs) monitored by time-lapse (every 15 min) 
phase-contrast microscopy with an inverted microscope (TE300; Nikon), 
a 10× DIC-L objective, 0.3 NA, a 5-Mhz digital camera (MicroMax; 
  Princeton Instruments), and QED software (Media Cybernetics).
Haptotactic cell migrations on Boyden chamber transwells (24-well 
cell culture inserts of polyethylene terephthalate membranes with 8-μm 
pores; Becton Dickinson) moved from serum-free DME to DME supple-
mented with 10% FBS over 6 h (Xu et al., 1998). BioCoat Matrigel inva-
sion chambers with 8-μm pores (BD Biosciences) in 24-well plates were 
seeded with 15,000 or 30,000 cells for 4- or 24-h migration. Migratory 
cells in ﬁ  ve ﬁ  elds per well (20× phase objective) were counted for three 
  individual wells per condition.
Immunoﬂ  uorescence
Cell staining followed established procedures, using the primary antibodies 
described in Antibodies and Alexa Fluor secondary antibodies and phal-
loidin (Invitrogen). Cell images were captured at room temperature using a 
ﬂ   uorescent microscope (AxioPhot; Carl Zeiss MicroImaging Inc.) with a 
Plan-Apochromat 63×, 1.40 NA, oil objective and 100×, 1.30 NA, and 
40×, 1.30 NA, objectives, a MicroMax digital camera (Princeton Instru-
ments), and Openlab imaging software (Improvision), and were incorporated 
into ﬁ  gures using Photoshop 8.0 and Illustrator 11.0 software (Adobe).
Protein analysis
Cell and tissue lysates were prepared, electrophoresed, and immunoblot-
ted as previously described (Hoffman et al., 2003). 2D gel analysis used 
the Protean IEF Cell system with immobilized pH gradient gel strips 
(pH 3–10; Bio-Rad Laboratories) followed by denaturing 10% acrylamide 
gels. For MS analysis, proteins were stained with Colloidal blue (Invitrogen), 
excised from the gel, washed twice in 50% acetonitrile/H2O, and then 
frozen. Peptide digestion, puriﬁ  cation, tandem array-liquid chromatography 
LC/MS-MS, and sequence analysis were performed at the University of 
Utah Mass Spectrometry Core Facility (Salt Lake City, UT) and at the 
Harvard Microchemistry Facility (Cambridge, MA) by microcapillary reverse-
phase HPLC nanoelectrospray tandem mass spectrometry (μLC MS/MS) 
on a quadrupole ion trap mass spectrometer (Finnigan LCQ DECA XP; 
Thermo Electron Corporation).
SFTI
SFTI was quantitated based on erosion spatial ﬁ   ltering (Russ, 2002). 
An erosion ﬁ  lter is equal to the ninth rank ﬁ  lter, which sorts 9 pixels in 
a 3 × 3 pixel matrix by their pixel brightness and replaces the center pixel 
with the darkest value found in the matrix. This “erodes” contours of objects 
in the digital image. Decay curves of averaged brightness during ﬁ  ltration 
cycles reﬂ  ect thickness of the original lines. Nonlinear curve ﬁ  t was applied 
to compute decay constants of the brightness curves and were termed SFTI. 
This method was superior to other methods based on line proﬁ  les because 
it reﬂ  ected thickness of lines in areas, rather than at points.
Statistics
Data analysis included analysis of variance between groups and unpaired 
t tests using GraphPad Prism software (GraphPad Software). A P value 
of <0.05 was considered statistically signiﬁ  cant.
Online supplemental material
Additional examples of the Mena and VASP mislocalization in the zyxin-null 
ﬁ  broblasts are available in Fig. S1. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200512115/DC1.
Antibodies were provided by M. Petit, W. Van de Ven, F. Gertler, T. Hirota, 
and H. Saya. K. Andrews made the GFP-zyxin retrovirus using DNA from 
F. Gage and cells from G. Nolan. W.S. Lane (Harvard Microchemistry Facility) 
and P. Krishna (University of Utah Mass Spectrometry Core Facility) provided 
advice and mass spectrometry analysis. University of Utah Core resource direc-
tors R. Schackmann, W. Green, C. Rodesch, and A. Szabo provided techni-
cal support. Comments from members of the Beckerle laboratory and graphic 
design by Diana Lim were invaluable.
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